ATRC · XBRL financial data

AtriCure financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ATRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	206,531	274,329	330,379	399,245	465,307	534,528
Cost of revenue	57,222	68,469	84,439	98,875	117,783	133,749
Cost of goods and services sold	655	—	—	—	—	—
Gross profit	149,309	205,860	245,940	300,370	347,524	400,779
Research and development	43,070	48,506	57,337	73,915	96,178	99,209
Selling, general and administrative	150,472	204,649	231,272	253,138	291,359	311,017
Total operating expenses	193,542	150,655	288,609	327,053	387,537	410,226
Operating income (loss)	(44,233)	55,205	(42,669)	(26,683)	(40,013)	(9,447)
Interest income	1,101	466	1,994	3,792	4,434	4,479
Interest expense	4,885	4,918	4,986	6,925	6,407	5,878
Other income (expense)	(24)	(366)	(537)	(31)	(326)	683
Income tax expense (benefit)	114	188	268	591	1,024	1,285
Net income (loss)	(48,155)	50,199	(46,466)	(30,438)	(44,698)	(11,448)
Earnings per share, basic USD per share	(1.14)	1.11	(1.02)	(0.66)	(0.95)	(0.24)
Earnings per share, diluted USD per share	(1.14)	1.09	(1.02)	(0.66)	(0.95)	(0.24)
Weighted average shares, basic thousands of shares	42,125	45,066	45,740	46,309	46,965	47,750
Weighted average shares, diluted thousands of shares	42,125	46,039	45,740	46,309	46,965	47,750

Fiscal years (ATRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	41,944	43,654	58,099	84,310	122,721	167,428
Short-term investments	202,274	75,436	63,014	52,975	0	—
Accounts receivable	23,146	33,021	42,693	52,501	60,339	66,653
Inventory	35,026	38,964	45,931	67,897	75,335	78,492
Prepaid and other current assets	4,347	5,001	5,477	8,563	9,431	9,944
Total current assets	306,737	196,076	215,214	266,246	267,826	322,517
Property and equipment, net	28,290	31,409	—	—	—	—
Right-of-use asset	1,914	4,761	3,787	4,324	5,727	6,868
Goodwill	234,781	234,781	234,781	234,781	234,781	234,781
Total assets	714,539	615,312	585,448	613,932	609,328	654,179
Accounts payable	12,736	18,597	19,898	27,354	25,032	25,310
Accrued liabilities	27,984	36,092	33,022	44,682	45,587	53,089
Current portion of long-term debt	6,667	—	—	—	—	—
Total current liabilities	49,137	56,445	58,392	74,569	73,424	81,520
Long-term debt	53,435	59,741	56,834	60,593	61,865	61,865
Lease liability, non-current	1,180	4,068	3,095	3,307	4,579	5,541
Total liabilities	302,145	131,556	128,694	147,764	148,359	162,244
Accumulated deficit	(330,352)	(280,153)	(326,619)	(357,057)	(401,755)	(413,203)
Total stockholders' equity	412,394	483,756	456,754	466,168	460,969	491,935
Total liabilities and equity	714,539	615,312	585,448	613,932	609,328	654,179
Common shares outstanding (cover page) thousands of shares	45,573	46,027	46,568	47,588	48,880	49,810

Fiscal years (ATRC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(48,155)	50,199	(46,466)	(30,438)	(44,698)	(11,448)
Stock-based compensation	22,642	28,078	28,771	35,728	40,405	44,685
Net cash from operating activities	(19,869)	(13,780)	(22,141)	4,484	12,204	57,334
Purchases of property and equipment	5,259	9,753	16,881	11,998	11,459	9,050
Net cash from investing activities	(156,198)	23,504	44,006	21,817	30,234	(14,550)
Proceeds from issuing common stock	188,958	0	0	—	—	—
Proceeds from long-term debt	0	5,000	0	0	61,210	0
Net cash from financing activities	189,392	(7,642)	(7,059)	(32)	(3,603)	1,176
Net change in cash	13,461	1,710	14,445	26,211	38,411	44,707

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
AtriCure	167,786	153,604	22,192*	50.9M	—	Q2 FY26 10-QJun 30, 2026
Lemaitre Vascular	26,625	not reported	15,965*	22.9M	—	Q2 FY26 10-QJun 30, 2026
Artivion	77,316	125,757	(1,266)*	48.8M	61.1 quarters	Q2 FY26 10-QJun 30, 2026
Ufp Technologies	9,045	173,964	15,612*	7.7M	—	Q2 FY26 10-QJun 30, 2026
Alphatec Holdings	79,936	221,172	18,856*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	62,818	254,560	(34,630)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Enovis	12,563	582,782	75,032*	57.7M	—	Q2 FY26 10-QJul 3, 2026
CONMED	47,972	335,557	49,411*	29.8M	—	Q3 FY26 10-QSep 30, 2026
Haemonetics	223,384	339,380	52,323	45.5M	—	Q1 FY27 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.